SA
Go ProLog In
OMER
OverviewIntelligenceChart
Next earnings: Aug 13, 2026 · After close
Signal
Leaning Bullish2↑1↓
Price
1↓
Move↓-7.76%Selling pressure
Volume
1↑
Volume↑2.9× avgSurge — unusual activity
Technical
1↑
RSI↑RSI 62Momentum positive
PRICE
Prev Close
13.28
Open
12.86
Day Range11.80 – 13.00
11.80
13.00
52W Range2.95 – 17.65
2.95
17.65
63% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
10.8x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
1.87
High vol
Performance
1D
-7.76%
5D
-16.21%
1M
—
3M
+4.79%
6M
+55.65%
YTD↓
-28.70%
1Y↑
+210.13%
Best: 1Y (+210.13%)Worst: YTD (-28.70%)
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
thin -12% gross margin
Valuation
CHEAP
P/E 11x vs ~20x sector
Health
MODERATE
CR 3.0 · FCF negative
Lean Bullish
Key MetricsTTM
Market Cap$886.60M
Revenue TTM$9.89M
Net Income TTM$86.17M
Free Cash Flow-$94.78M
Gross Margin-12.4%
Net Margin871.0%
Operating Margin-1063.9%
Return on Equity-54.4%
Return on Assets30.1%
Debt / Equity-0.19
Current Ratio3.03
EPS TTM$1.20
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong4 concern
35/100
Liquidity
3.03Strong
Leverage
-0.19Strong
Coverage
-17.8xConcern
ROE
-54.4%Concern
ROIC
-44.1%Concern
Cash
$10MConcern
ANALYST COVERAGE19 analysts
BUY
▲ +226.5%upside to target
Strong Buy
15%
Buy
1053%
Hold
632%
Sell
211%
11 Buy (58%)6 Hold (32%)2 Sell (10%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
7/10
Technicals
●
RSI RangeRSI 62 — Bullish momentum
✓
Volume
●
Volume FlowDistribution — institutional selling
✗
Fundamentals
●
Last EarningsBeat estimates
✓
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 3.03 — healthy liquidity
✓
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentSep 18, 2026
In 125 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBULLISH
Technicals →

Trend

▲ UptrendGolden Cross · 50D leads 200D by 34.1%

+0.2% vs SMA 50 · +34.4% vs SMA 200

Momentum

RSI62.3
Positive momentum, not extended
MACD+0.59
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$17.65+44.1%
EMA 50
$12.76+4.2%
Current
$12.25
EMA 200
$9.09-25.8%
52W Low
$2.95-75.9%
52-Week RangeMid-range
$2.9563th %ile$17.65
Squeeze SetupVolume-based
Distribution Pressure

Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.

20-Day Money Flow
Acc days:3
Dist days:4
Edge:+1 dist
Volume Context
Avg Vol (50D)1.2M
Recent Vol (5D)
2.2M+83%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 3 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$2.5M
$1.7M–$4.7M
—-$2.03—
±50%
Moderate3
FY2026(current)
$84.5M
$55.7M–$157.2M
▲ +3245.5%$0.20—
±50%
Low1
FY2027
$199.2M
$131.4M–$370.7M
▲ +135.8%$0.27▲ +34.0%
±50%
Low2
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 4 consecutive quarters
Earnings HistoryOMER
Last 8Q
+99.7%avg beat
Beat 7 of 8 quartersMissed 1↑ Estimates rising
+2%
Q3'24
+9%
Q4'24
+19%
Q1'25
-14%
Q2'25
+4%
Q3'25
+67%
Q4'25
+671%
Q1'26
+40%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
UBSNeutral
Dec 8
DOWNGRADE
Insider Activity
SEC Filings →
2 Buys/4 SellsNet Selling
Borges David J.VP, Finance & …
$382K
Jan 12
SELL
Borges David J.VP, Finance & …
$369K
Jan 13
SELL
Demopulos Gregory A…Chairman, CEO …
$25K
Nov 17
BUY
Demopulos Peter A MdDir
$15K
Nov 15
BUY
Hanish Arnold CDir
$32K
May 22
SELL
Cable Thomas J.Dir
$33K
May 22
SELL
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
BlackRock, Inc.
5.3M▲
2
INGALLS & SNYDER LLC
3.6M▲
3
UBS Group AG
2.3M▲
4
STATE STREET CORP
1.9M▲
5
STIFEL FINANCIAL CORP
1.8M▲
6
GEODE CAPITAL MANAGEMENT, LLC
1.8M▲
7
CI Private Wealth, LLC
801K▲
8
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
583K▼
News & Activity

OMER News

19 articles · 4h ago

About

omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Gregory Demopulos
Website
omeros.com ↗
Catherine A. MelfiChief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems
George A. GaitanarisChief Scientific Officer & Vice President of Science
Gregory A. DemopulosCo-Founder, Chairman, Chief Executive Officer & President
Peers— Health Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt Cap↓P/ERev GrwMarginELO
OMER◀
$12.25-7.76%$887M10.2——1500
BBIO
$66.13-5.07%$13.0B—+12626.1%-14525.8%1500
GH
$94.92-3.79%$12.6B—+3288.2%-4239.0%1500
MDGL
$523.69-3.00%$12.1B—+43205.3%-3008.0%1500
AXSM
$227.72-1.30%$11.7B—+6554.5%-2868.8%1500
BTSG
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
ARWR
$76.67-3.79%$10.8B—+2325815.3%-19.7%1500
Sector avg—-3.65%—30.3+398824.8%-4085.6%1500

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance